Open an account

AtriCure

ATRC · NASDAQ

$57.67+$2.14 (+3.85%)TodayMarket closed ·
Prev close $55.53

About ATRC

AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. The company is headquartered in Mason, Ohio and currently employs 1,350 full-time employees. The company went IPO on 2005-08-05. The firm's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The firm's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.

Employees
1,350
Headquarters
Mason, Ohio
Listed
Aug 5, 2005
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
atricure.com

ATRC key statistics

Market cap
2.93B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
987.85K
Volume
446.40K
Open price
$55.64
High today
$58.20
Low today
$55.64
52 Week high
$61.70
52 Week low
$25.36

AtriCure (ATRC) at a glance

As of Oct 20, 2026, AtriCure (ATRC) shares are priced at $57.67, giving the company a market cap of 2.93B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $55.64 and $58.20. The current price is 3.6% above the day's low and 0.9% below its high.

Volume so far is 446.40K shares, below the average of 987.85K shares a day.

Over the past year AtriCure has ranged from $25.36 to $61.70, and now sits 89% of the way up that range.

AtriCure met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $0.18 per share against an estimate of $0.0045.

The average analyst price target is $56.61, 1.8% below the current price, from 11 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

82%of 11 analyst ratings say Buy
  • Buy81.8%
  • Hold18.2%
  • Sell0.0%
Price target · 11 analystsAvg $56.61
Low
$43.43
Now
$57.67
High
$68.25

ATRC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 555.2% on average.

  1. Q3 FY24: reported -$0.17 per share against an estimate of -$0.1986
  2. Q4 FY24: reported -$0.08 per share against an estimate of -$0.234
  3. Q1 FY25: reported -$0.14 per share against an estimate of -$0.2336
  4. Q2 FY25: reported -$0.02 per share against an estimate of -$0.1711
  5. Q3 FY25: reported -$0.01 per share against an estimate of -$0.1171
  6. Q4 FY25: reported $0.04 per share against an estimate of -$0.0969
  7. Q1 FY26: reported $0.00 per share against an estimate of -$0.0601
  8. Q2 FY26: reported $0.18 per share against an estimate of $0.0045

ATRC news

  • Press releaseBusiness Wire

    AtriCure to Announce Third Quarter 2026 Financial Results

  • Press releasePRNewswire

    Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

  • Press releaseBusiness Wire

    AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

  • Press releaseBusiness Wire

    AtriCure to Participate at Upcoming Investor Conferences

  • AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript

  • Press releaseBusiness Wire

    AtriCure Reports Second Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    AtriCure to Announce Second Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference

Similar companies

Companies in the same industry as AtriCure

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.